Key Details
Price
$0.24Annual ROE
-32.21%Beta
-2.32Events Calendar
Next earnings date:
May 15, 2025Recent quarterly earnings:
Nov 15, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
July 20, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn.
KUALA LUMPUR, Malaysia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing of a strategic partnership Memorandum of Understanding (MOU) with Shenzhen Rongguang Health Group, a major healthcare services provider in China. This partnership aims to expand the Company's expertise and presence in cancer screening, precision medicine, and preventative healthcare through its subsidiary MRNA Scientific Sdn Bhd.
KUALA LUMPUR, Malaysia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, the “Company”), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), has invested approximately RM 2 million (approx. USD $450,000) to begin the production of fine-quality color paste (non-drying type) specifically designed for composite industrial customers. The new production facility will commence operations in late September 2024, marking a significant milestone for the Company as it seeks to expand its portfolio and enhance its market presence globally.
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia Co-Investment Fund (MyCIF), into Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside BGLC's recent investment, the first under its Environmental & Social Impact (ESI) Scheme shows confidence in the strategic direction and potential of AISB.
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysian healthcare technology firm. This strategic investment, executed through BGLC's wholly-owned subsidiary, MRNA Scientific Sdn Bhd, solidifies BGLC's commitment to advancing AI-driven healthcare solutions.
BioNexus (NASDAQ: BGLC ) stock is rocketing higher on Tuesday despite a lack of news concerning the chemical raw material products company. Instead, traders are seeing shares of BGLC stock rally this morning alongside heavy trading.
BioNexus Gene Lab (NASDAQ: BGLC ) stock is taking off on Friday after the company uplisted its shares to the Nasdaq Capital Market. That saw the company's shares start trading on the Nasdaq Capital Market yesterday.
FAQ
- What is the primary business of BioNexus Gene Lab?
- What is the ticker symbol for BioNexus Gene Lab?
- Does BioNexus Gene Lab pay dividends?
- What sector is BioNexus Gene Lab in?
- What industry is BioNexus Gene Lab in?
- What country is BioNexus Gene Lab based in?
- When did BioNexus Gene Lab go public?
- Is BioNexus Gene Lab in the S&P 500?
- Is BioNexus Gene Lab in the NASDAQ 100?
- Is BioNexus Gene Lab in the Dow Jones?
- When was BioNexus Gene Lab's last earnings report?
- When does BioNexus Gene Lab report earnings?